PFENYSEPharmaceutical PreparationsFiscal year ends December 31
PFIZER INC
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026
$29.44−0.14 (-0.47%)
Close on Oct 19, 2026
- Market cap
- $167.78B
- P/E (TTM)
- 38.7
- Dividend yield
- 5.84%
PFIZER INC revenue by segment
By business segment
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biopharma [Member] | $62.28B | $61.92B | $61.20B | $61.47B | $62.55B | $61.24B | $62.40B | $59.17B | $54.97B | $54.67B | $58.24B | $68.81B | 97.8% | -0.4% |
| Business Innovation Segment [Member] | – | – | – | – | – | – | – | – | – | $1.28B | $1.31B | $1.30B | – | – |
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product [Member] | $51.99B | $52.08B | $51.66B | $52.25B | $53.75B | $52.67B | $53.82B | $51.07B | $47.24B | $47.14B | $50.91B | – | 81.6% | -3.3% |
| Royalty [Member] | $1.79B | $1.74B | $1.65B | $1.60B | $1.55B | $1.47B | $1.42B | $1.31B | $1.19B | $1.12B | $1.06B | – | 2.8% | +15.3% |
| Pfizer CentreOne [Member] | $1.42B | $1.39B | $1.34B | $1.29B | $1.23B | $1.16B | $1.15B | – | – | – | – | – | 2.2% | +14.9% |
| Paxlovid, NDA-Labeled, U.S. Strategic National Stockpile [Member] | – | – | – | – | – | – | $442.00M | – | – | – | – | – | – | – |
| Pfizer Ignite [Member] | – | – | $41.00M | $63.00M | $88.00M | $83.00M | $82.00M | – | – | – | – | – | – | – |
By region
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $37.40B | $37.44B | $37.08B | $37.18B | $38.55B | $37.55B | $38.69B | $34.38B | $30.38B | $28.95B | $28.15B | $32.56B | 58.7% | -3.0% |
| International Developed Markets [Member] | $16.79B | $16.44B | $16.19B | $16.55B | $16.27B | $16.04B | $16.06B | $17.59B | $17.51B | $18.47B | $20.91B | – | 26.4% | +3.2% |
| International Emerging Markets [Member] | $9.51B | $9.44B | $9.31B | $9.06B | $9.01B | $8.88B | $8.88B | $8.46B | $8.33B | $8.52B | $10.50B | – | 14.9% | +5.5% |
| Developed Rest of World [Member] | – | – | – | – | – | – | – | – | – | – | $7.76B | $9.96B | – | – |
| Emerging Markets [Member] | – | – | – | – | – | – | – | – | – | – | $12.00B | $13.11B | – | – |
| Developed Europe [Member] | – | – | – | – | – | – | – | – | – | – | $11.65B | $14.50B | – | – |
From the segment and revenue-disaggregation notes of Pfizer's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.